Maleimide as the PEG end-group promotes macrophage-targeted drug delivery of PEGylated nanoparticles in vivo by enhancing interaction with circulating erythrocytes
Xin Wang, Xiandi Meng, Kuirong Mao, Hongmei Chen, Xiuxiu Cong, Feiqi Liu, Jialiang Wang, Shuhan Liu, Yanbao Xin, Ge Zhu, Huizhu Tan, Yong‐Guang Yang, Tianmeng Sun
Topics & Concepts
In vivoDrug deliveryPEG ratioInfiltration (HVAC)Mononuclear phagocyte systemImmune systemPaclitaxelPharmacologyChemistryMaleimideMacrophageBiophysicsIn vitroMaterials scienceCancer researchImmunologyMedicineBiochemistryNanotechnologyChemotherapyBiologyInternal medicinePolymer chemistryEconomicsComposite materialFinanceBiotechnologyNanoplatforms for cancer theranosticsImmune cells in cancerPhagocytosis and Immune Regulation